Tenax Therapeutics, Inc.
9 clinical trials · Sponsor
◉ Watch Tenax Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Long-Term Open-Label Extension Study of Oral Levosimendan (NCT07436689) | Tenax Therapeutics, Inc. | 2026-03-13 |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (NCT07288398) | Tenax Therapeutics, Inc. | 2026-03-03 |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (NCT05983250) | Tenax Therapeutics, Inc. | 2024-01-10 |
| Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients (NCT03624010) | Tenax Therapeutics, Inc. | 2019-04-09 |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF (NCT03541603) | Tenax Therapeutics, Inc. | 2018-11-14 |
Track Tenax Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.